Cantor Fitzgerald initiated coverage on Clene with a new price target
$CLNN
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of Clene with a rating of Overweight and set a new price target of $22.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/4/2022 | Outperform → Perform | Oppenheimer | |
| 7/18/2022 | $16.00 | Buy | H.C. Wainwright |
| 5/2/2022 | $10.00 | Buy | Canaccord Genuity |
| 9/28/2021 | $20.00 | Outperform | Oppenheimer |
Oppenheimer downgraded Clene from Outperform to Perform
H.C. Wainwright initiated coverage of Clene with a rating of Buy and set a new price target of $16.00
Canaccord Genuity initiated coverage of Clene with a rating of Buy and set a new price target of $10.00
Clene met with the U.S. Food and Drug Administration (FDA) on November 1, 2024, in a Type C meeting to discuss the potential for an accelerated approval pathway in ALS and are awaiting meeting minutesCash, cash equivalents and marketable securities of $14.6 million as of September 30, 2024Amended debt agreement with Avenue Capital to defer principal payments and extend maturity of facility to second quarter of 2025Completed registered direct offering and concurrent private placements to raise $7.3 million in gross proceeds on October 1, 2024 SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Cl
SALT LAKE CITY, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in October. 2024 Maxim Healthcare Virtual SummitDate: October 15-17, 2024Location: VirtualPresentation: October 15, 2024, at 2:30 p.m. E.T.Format: Fireside Presentation and 1x1 meetingsAttendance: Sign up to become an M-Ve
Investment led by healthcare-focused institutional investor with participation from SymBiosis; founding investor Kensington Capital Holdings; Clene's Chairman of the Board of Directors, Chief Executive Officer and Chief Scientific Officer and Founder; along with support from several other previously existing shareholders$7.3 million registered direct offering and concurrent private placements priced at market under Nasdaq rulesAmended debt facility with Avenue Venture Opportunities Fund, L.P. in conjunction with financingAggregate financing, including amendment to debt facility, expected to be sufficient to fund Company into the first quarter of 2025, including a face-to-face meeting with th
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
4 - Clene Inc. (0001822791) (Issuer)
The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeksPrespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of death or risk of death/permanently assisted ventilation at 24 weeks Survival signal consistent with prior results from the Phase 2 RESCUE-ALS trialClene will continue the open-label extension of CNM-Au8 in the Healey ALS Platform Trial and is in discussions with the Healey & AMG ALS Center to design and offer an Expanded Access Protocol (EAP) of CNM-Au8 30mg for eligible participants of closed regimens and othersClene is pursuing multiple paths, including ongoi
SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will report topline results of the CNM-Au8® regimen of the HEALEY ALS Platform Trial on Monday, Oct. 3. Clene's management team will host a conference call and webcast to discuss the results. Conference Call and Webcast DetailsTime and Date: 8:30 a.m. EDT on Oct. 3, 2022Investors: 1 (888) 660-6179 (toll-free) or 1 (929) 203-1946 (toll)Conference ID: 5318408Webcast Link A live audio
CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT populationConsistent improvements favoring CNM-Au8 were seen across paraclinical biomarkers, providing physiological evidence for its potential neuroprotective and remyelinating effectsCNM-Au8 treatment was well-tolerated, and there were no significant safety findings reportedResults provide support to advance CNM-Au8 into Phase 3 clinical developmentClene to host a call and webcast at 7:30 am EDT today SALT LAKE CITY, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiarie
SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Benjamin Greenberg, M.D., M.H.S. as Head of Medical. An internationally recognized expert in treating disorders of the central nervous system, Dr. Greenberg brings extensive clinical and research experience to Clene as the company continues its development of CNM-Au8® as a potential treatment for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). "Dr. Green
SALT LAKE CITY, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Morgan Brown as Chief Financial Officer effective Feb. 1, 2022. "Morgan joins the executive team at a pivotal time in Clene's growth," stated Clene's President and CEO, Rob Etherington. "He is a seasoned healthcare executive and public-company biopharma CFO, who has led the out-licensing of commercial stage assets and M&A transactions as well as numerous substantial equity and
SALT LAKE CITY, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced the appointment of Vallerie V. McLaughlin, MD, to its board as its seventh independent director. Dr. McLaughlin is the Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine, Associate Chief Clinical Officer for Cardiovascular Services of the University of Michigan Medical Group, Associate Chief, Division of Cardiovascular Medicine, and Director of the Pulm
424B3 - Clene Inc. (0001822791) (Filer)
S-3 - Clene Inc. (0001822791) (Filer)
8-K - Clene Inc. (0001822791) (Filer)
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dipping 2% on Thursday. The Dow traded up 0.07% to 39,748.00 while the NASDAQ fell 2% to 18,274.88 . The S&P 500 also fell, dropping, 0.94% to 5,581.00. Check This Out: Top 4 Real Estate Stocks That Could Lead To Your Biggest Gains In Q3 Leading and Lagging SectorsReal estate shares jumped by 2.4% on Thursday. In trading on Thursday, information technology shares fell by 2.7%. Top Headline Delta Air Lines, Inc. (NYSE:DAL) posted downbeat second-quarter earnings and issued lower-than-expected third-quarter earnings outlook. Delta Air Lines reported quarterly earnings of $2.36 per share w
Shares of Conagra Brands, Inc. (NYSE:CAG) fell during Thursday's session after the company reported worse-than-expected fourth-quarter sales results and issued FY25 adjusted EPS guidance below estimates. The company reported adjusted earnings per share of 61 cents, beating the analyst consensus estimate of 57 cents. Quarterly revenues of $2.905 billion missed the street view of $2.930 billion, according to data from Benzinga Pro. Conagra Brands shares declined 3.9% to $27.70 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Kazia Therapeutics Limited (NASDAQ:KZIA) shares surged 88.6% to $1.26. Kazia Therapeutics, on Wednesday, announced result
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 300 points on Thursday. The Dow traded up 0.21% to 39,803.00 while the NASDAQ fell 1.81% to 18,310.23. The S&P 500 also fell, dropping, 0.84% to 5,586.74. Check This Out: Top 4 Real Estate Stocks That Could Lead To Your Biggest Gains In Q3 Leading and Lagging SectorsReal estate shares jumped by 2.8% on Thursday. In trading on Thursday, information technology shares fell by 2.7%. Top Headline PepsiCo Inc (NASDAQ:PEP) reported worse-than-expected second-quarter FY24 revenue. The company reported second-quarter sales growth of 0.8% year-on-year to $22.501 billion, missing the analys
SC 13G/A - Clene Inc. (0001822791) (Subject)
SC 13G - Clene Inc. (0001822791) (Subject)
SC 13D/A - Clene Inc. (0001822791) (Subject)